S ystemic lupus erythematosus (SLE) is a chronic autoimmune disease with strong genetic and environmental components. [1] [2] [3] Autoantibodies play an important role in the pathogenesis of SLE, and the diverse clinical manifestations of the disease are caused by the deposition of antibody-containing immune complexes in blood vessels, leading to inflammation in the kidney, brain, and skin. Direct pathogenic effects of the autoantibodies contribute to hemolytic anemia and thrombocytopenia.
During the past 20 years, many linkage and candidate-gene studies have been performed to identify genetic factors contributing to a susceptibility to SLE. For example, haplotypes carrying the HLA class II alleles DRB1*0301 and DRB1*1501 are clearly associated with SLE and the presence of antibodies to nuclear autoantigens. [4] [5] [6] More recently, variants of the genes encoding interferon regulatory factor 5 (IRF5) and signal transducer and activator of transcription 4 (STAT4) have been discovered to be risk factors for SLE. [7] [8] [9] [10] The identification of IRF5 and STAT4 as SLE risk genes supports the hypothesis that the type I interferon pathway is central to disease pathogenesis. [11] [12] [13] [14] In this report, we describe the results of a genomewide scan of samples from North American subjects of European descent (1311 case subjects with SLE and 3340 control subjects) and a replication analysis of Swedish case-control subjects. We identify two novel genetic lociC8orf13-BLK and ITGAM-ITGAX -that contribute to the risk of SLE.
Me thods

Subjects
Case subjects included 1435 patients with SLE for whom DNA samples were obtained from the following collections: 338 from the Autoimmune Biomarkers Collaborative Network, a repository funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases 15 ; 141 from the Multiple Autoimmune Disease Genetics Consortium 16 ; 613 from the University of California, San Francisco (UCSF), Lupus Genetics Project 10,17 ; 335 from the University of Pittsburgh Medical Center 18 ; and 8 from the Feinstein Institute for Medical Research. The European descent of all case subjects with SLE was determined by self-report with the use of a multiple-choice questionnaire. (In general, subjects needed to have at least three grandparents of European origin.) The diagnosis of SLE (fulfillment of four or more of the criteria of the American College of Rheumatology [ACR] 19 ) was confirmed in all cases by review of medical records (for 94% of case subjects) or by written documentation of criteria by the treating rheumatologist (6%). Clinical data were reviewed and tabulated at each institution. The counts and percentages for each of the 11 ACR classification criteria for SLE 19 are listed in Table  1 of the Supplementary Appendix (available with the full text of this article at www.nejm.org).
A total of 3583 samples from control subjects were examined in the association analyses. As part of this project, 1861 control samples from the New York Cancer Project collection 20 were selected and then genotyped on the basis of selfdescribed ancestral origin, sex, and age. In addition, genotype data from 1722 control samples (all self-described North Americans of European descent) were obtained from the publicly available iControlDB database (www.illumina.com/ pages.ilmn?ID=231).
To test for replication, we genotyped DNA from an independent collection of samples from 793 Swedish patients with SLE (all of whom fulfilled four or more of the classification criteria for SLE, as defined by the ACR) and 857 healthy Swedish control subjects. The patients were from rheumatology clinics at the Lund, Uppsala, Karolinska (Solna), and Umeå University Hospitals. 7 The institutional review board at each collaborating center approved the study, and all subjects gave informed written consent.
Genotyping
A total of 1861 samples from control subjects from the New York Cancer Project were genotyped on the Illumina HumanHap550 Genotyping BeadChip 21 at the Feinstein Institute. A total of 1465 samples (464 from case subjects and 1001 from control subjects) were genotyped on the HumanHap550v1 chip, and 1875 samples (1015 from case subjects and 860 from control subjects) were genotyped on the HumanHap550v3 chip. Genotype data from 1452 of the control samples were submitted to iControlDB and made publicly available in 2007. An additional, independent set of 1722 samples that were genotyped on the HumanHap550 BeadChip was obtained from studies 66 and 67 of the iControlDB. Samples from case subjects were genotyped at the Feinstein Institute in serial phases; series 1 consisted of the 479 case subjects from the Autoimmune Biomarkers Collaborative Network and Multiple Autoimmune Disease Genetics Consortium, series 2 consisted of the 613 case subjects from the UCSF Lupus Genetics Project, and series 3 consisted of the 387 case subjects from the University of Pittsburgh Medical Center and the Feinstein Institute. The 545,080 single-nucleotide polymorphisms (SNPs) present on both HumanHap550 versions 1 and 3 were advanced into the analysis. Case and control samples with average call rates of less than 80% across the chip underwent repeated genotyping.
In the Swedish series, the SNPs rs11574637 (ITGAM-ITGAX) and rs13277113 (C8orf13-BLK) were genotyped with the use of homogeneous single-base extension assays with fluorescence polarization detection at the SNP Technology Platform in Uppsala (www.genotyping.se) and reagents (PerkinElmer). 22 The genotype call rate in the samples was 96%, and the reproducibility was 100%, on the basis of duplicate assays of 4.6% of the genotypes. Samples from a three-generation pedigree from the Centre d'Etude du Polymorphisme Humain (CEPH) with 20 members were genotyped in parallel with the study samples, and no deviation from mendelian inheritance was observed for either of the SNPs.
Data-Quality Filters
Details on the data-quality filters used in the study, tests for association and for heterogeneity among the three case-control studies, and removal of population outliers with the use of EIGENSTRAT software 23 are available in the Supplementary Appendix. Series 1 consisted of 411 case subjects and 1047 control subjects, series 2 consisted of 595 case subjects and 1516 control subjects, and series 3 consisted of 305 case subjects and 777 control subjects. Overall, women accounted for 93% of case subjects and 62% of control subjects. No significant differences in allele frequencies were noted between men and women.
A total of 3323 SNPs were removed because more than 2% of data were missing in at least one series or missing data were unequally distributed between case and control subjects (differential missingness, P<1×10 −3 ). Another 13 SNPs in the pseudoautosomal region of chromosome X showed no significant association and were excluded from further analysis. Filtering of samples and markers was conducted with the use of analytical modules within the PLINK software program. 24 For each series, a total of 502,033 SNPs were advanced into downstream analyses.
Gene-Expression Analysis
We examined gene expression in B-cell lines transformed by the Epstein-Barr virus (EBV) from 210 unrelated, healthy HapMap subjects (GENEVAR project, www.sanger.ac.uk/humgen/genevar/) 25 and an independent set of 400 EBV-transformed B cells. 26 Additional details regarding these analyses are available in the Supplementary Appendix.
Statistical Analysis
The association between all SNPs and a susceptibility to SLE was calculated with the use of twoby-two contingency tables. A genomic control inflation factor (λ gc ) was then calculated for each sample series. 27 The genomic control inflation factor is a metric based on the median chi-square that reflects whether the bulk of the distribution conforms to the null hypothesis (λ gc = 1.0). A λ gc value of more than 1 indicates an elevation of the average chi-square association statistic owing to systemic technical artifacts or the presence of population stratification. The 50 loci with the strongest associations are listed in Table 2 of the Supplementary Appendix, and the corrected summary statistics of population stratification for all SNPs passing quality-control filters from each series and the combined association statistics are available from dbGAP (accession number phs000122.v1.p1).
R e sult s
Genomewide Association Analysis
A total of 502,033 SNPs on the Illumina chips passed quality-control filters and were tested for association with SLE in a staged fashion with the use of three case-control series (Table 1) . A combined association statistic was calculated by the addition of the z scores converted from the EIGENSTRAT-corrected chi-square test statistic, 23 weighted for series size and adjusted for the residual λ gc of each series (see the Supplementary Appendix).
A comparison of the observed P values for the meta-analysis with the P values for a null distribution is shown in Figure 1A . Significant deviation from the null distribution was observed at the tail of the distribution, which may indicate the presence of true positive associations. A strong as- sociation with SLE was noted for three established risk loci. In the HLA class II region, rs2187668 is a near perfect predictor of the DRB1*0301 allele 28 and was the variant most strongly associated with SLE in the combined analysis (P = 3×10 −21 ). An additional 157 SNPs in the HLA region, many of which are correlated with the DRB1*0301 allele, had observed P values of less than 5×10 −7 (Fig. 1B) . A strong association was observed with variants linked to the well-validated risk haplotype of IRF5 (e.g., rs10488631; P = 2×10 −11 ). [7] [8] [9] In addition, an association with STAT4 was observed (rs7574865, P = 9×10 −14 ). An association between STAT4 variants and both SLE and rheumatoid arthritis was reported recently. 10 Our SLE data set overlaps with that of the earlier study 10 and includes an additional 341 case subjects and 2905 control subjects who were not included in the previous analysis. After removing variants in HLA, IRF5, and STAT4 from the expected versus observed chi-square analysis, a deviation of P values from the null distribution remained, suggesting the existence of novel SLE loci (Fig. 1A) . Multiple SNPs near the B lymphoid tyrosine kinase (BLK) gene and in a region that contains the integrin alpha M (ITGAM) and integrin alpha X (ITGAX) genes were highly associated with SLE in the combined analysis (Fig. 1B) . Neither of these genes or regions has previously been implicated in SLE susceptibility.
C8orf13-BLK
Several variants on the short arm of chromosome 8 (8p23.1) were associated with SLE ( Fig. 2 and Table 2, and Table 5 of the Supplementary Appendix). The A allele of rs13277113 was highly enriched in the sample from U.S. case subjects as compared with controls (P = 8×10 −8 ; combined odds ratio, 1.39; 95% confidence interval [CI], 1.26 to 1.54). To confirm this initial observation, an independent collection of 793 samples from SLE case subjects and 857 matched controls from Sweden was typed for rs13277113, and a convincing association between the minor A allele and SLE was also observed (P = 4×10 −4 ; odds ratio, 1.33; 95% CI, 1.13 to 1.55) ( Table 2) . A combined analysis of rs13277113 with the use of both the U.S. and Swedish samples showed P = 1×10 −10 , which meets the rigorous criterion of P<5×10 −8 for the significance of a genomewide association. 31 The SNP rs13277113 maps to the interval between two genes transcribed in opposite directions: BLK, a tyrosine kinase in the src family that signals downstream of the B-cell receptor, and C8orf13, a ubiquitously expressed gene of unknown function (Fig. 2) . No known coding-region variants of BLK or C8orf13 are in linkage disequilibrium with rs13277113.
Common genetic variation has been shown to correlate with levels of cis gene expression. 25, 26, 32 Using a gene-expression data set generated from transformed B-cell lines of 210 unrelated HapMap samples, 25 we observed that the risk A allele of rs13277113 was associated with lower levels of messenger RNA (mRNA) expression of BLK (Fig. 2B) . Homozygotes for the A allele had a level of expression that was approximately 50% of that of homozygotes for the G allele, and A/G heterozygotes had intermediate levels. The expression of the C8orf13 gene also correlated with the risk haplotype, but in the opposite direction. The A allele of rs13277113 was associated with higher expression of C8orf13 in the transformed lines, whereas the G allele was significantly associated with lower expression (Fig. 2C) In this data set, a marker in linkage disequilibrium with rs13277113 (rs4840568, r 2 = 0.77) was associated with both decreased expression of BLK (P = 9×10 −27 , probe 206255_at) and increased expression of C8orf13 (P = 5×10 −35 , probe 226614_ s_at), with effect sizes similar to those observed in the HapMap data set. Multiple conserved sites of transcription-factor binding, including motifs for interferon regulatory factor 1 (IRF1), peroxisome proliferatoractivated receptor gamma (PPARG), and an interferon-stimulated response element, are located in the 5′ region of BLK and C8orf13. However, neither rs13277113 nor variants in linkage disequilibrium (r 2 >0.5) altered known sites of transcription-factor binding or other known functional nucleic acid motifs. We conclude that rs13277113, or a variation that is strongly associated with rs13277113, alters the level of mRNA expression of BLK and C8orf13.
ITGAM-ITGAX
Variants within a cluster of genes encoding the integrin alpha chains on chromosome 16 were also significantly associated with SLE (Table 2 and Fig. 3 ). Reproducible association of the C allele of rs11574637 was observed across the three series of SLE cases (P = 5×10 −7 ; odds ratio, 1.30; 95% CI, 1.17 to 1.45). The C allele of rs11574637 showed similarly strong enrichment in the Swedish replication series (P = 4×10 −7 ; odds ratio, 1.59; 95% CI, 1.33 to 1.91) ( Table 2) , and combined analysis showed a combined P value of 3×10 −11 (Table 2) . SNP rs11574637 is part of a block of correlated SNPs that covers approximately 150 kb and encodes several genes, including ITGAM and the 5′ portion of ITGAX (Fig. 3A) . Both ITGAM and ITGAX are expressed at detectable levels in EBVtransformed B cells, but rs11574637 was not significantly associated with mRNA levels of either gene (data not shown).
Of potential interest is the observation that in the North American control subjects, rs11574637 was correlated with two nonsynonymous variants of ITGAM. The first SNP, rs1143678 (r 2 = 0.85), results in a Pro1146Ser substitution (association with SLE, P = 3×10 −5 ). The C allele of rs11574637 and the 1146Ser allele form a haplotype on 18.2% of control chromosomes; the C allele is also present on a distinct haplotype that is present on approximately 2% of chromosomes from controls lacking the 1146Ser allele. The second nonsynonymous SNP, rs1143683 (r 2 = 0.45 in HapMap CEU [CEPH Utah residents with ancestry from northern and western Europe]), results in an Ala858Val substitution and was not directly genotyped in this study. At this time it is not known whether the ITGAM nonsynonymous variants or additional alleles underlie the association within the ITGAM-ITGAX region.
Dis cus sion
By studying a large number of patients with SLE (1311) and an even larger group of control subjects (3340), we had excellent power to detect associations between SLE and genetic variants. The strong associations between SLE and SNPs in the HLA region, IRF5, and STAT4 serve as positive controls for the experiment and confirm that these loci confer susceptibility to SLE. The src family tyrosine kinase BLK is an interesting new candidate gene for SLE. Expression Panel A shows the −log 10 P values from the C8orf13-BLK region. The colors of the diamonds represent the r 2 correlations with rs13277113. All genes in the region (from the Reference Sequence database of the National Center for Biotechnology Information) are displayed above a plot showing the linkage disequilibrium in the region, as determined by analysis of control chromosomes. Blocks connecting pairs of SNPs are shaded according to the strength of the linkage disequilibrium between the SNPs, from 0.0 (white) to 1.0 (bright red), as measured by the disequilibrium coefficient D′. This associated region on chromosome 8 lies within a common polymorphic 4.2-Mb intrachromosomal inversion 29, 30 and is associated with unusually low levels of extended linkage disequilibrium across the region, as shown. However, the association between C8orf13-BLK and systemic lupus erythematosus is independent of the inversion. The expression of BLK (Panel B) and C8orf13 (Panel C) in transformed B-cell lines from 210 unrelated, healthy HapMap founders is shown, stratified according to genotype at rs13277113. The significance of the differential expression was determined with the use of unpaired Student's t-tests.
of BLK is highly restricted to the B-cell lineage. 33 Blk expression in mice is first observed in cycling late pro-B cells, continues throughout B-cell development, and is subsequently down-regulated in plasma B cells. 34 Mice that are deficient in Blk have no gross phenotype, 35 and we are not aware of studies of the function of BLK in human B cells. It has been hypothesized that BLK is one of the tyrosine kinases that transduces signals downstream of the B-cell receptor and that it has a redundant role in mice (given the lack of a phenotype in Blk-deficient mice). There is a precedent for major species differences in the role of kinases associated with the B-cell receptor. For example, in humans, a deficiency in Bruton's tyrosine kinase (BTK) leads to X-linked agammaglobulinemia and a complete lack of B cells. 36 However, deficiency of Btk in mice is associated with a much milder phenotype. 37 B-cell-receptor signaling is important for establishing the B-cell repertoire through induction of anergy, deletion, and receptor editing during B-cell development. 38,39 As our study shows, the risk allele at BLK is associated with reduced expression of BLK mRNA in transformed B-cell lines. We speculate that altered protein levels of BLK might influence tolerance mechanisms in B cells, predisposing persons to systemic autoimmunity. A similar mechanism has recently been shown for Ly108, one of the major genetic loci in the NZM2410 mouse model of lupus. 40 Our data also suggest an effect of the risk haplotype on expression of the ubiquitously expressed gene C8orf13, but the function of this gene is currently unknown.
We identified a second locus, ITGAM-ITGAX. Although we cannot exclude ITGAX because of the strong linkage disequilibrium in the region that extends into its 5′ region, we think that variants of ITGAM are driving the association. ITGAM (also known as CD11b, Mac-1, and complement receptor type 3) is a well-characterized molecule in the integrin alpha chain family that is expressed by a variety of myeloid cell types, including dendritic cells, macrophages, monocytes, and neutrophils. 41-43 ITGAM forms a heterodimer with integrin beta-2 (ITGB2, or CD18) and mediates adhesion between cell types in the immune system and the adhesion of myeloid cells to endothelium. 44 Mice that are deficient in ITGAM have enhanced disease progression and inflammation in several models of autoimmu- T h e n e w e ng l a n d j o u r na l o f m e dic i n e We thank Anthony Liew, Houman Khalili, and Alamelu Chandrasekaran for their assistance with genotyping; Alkes Price and Nick Patterson for their assistance with EIGENSTRAT software; and members of the Molecular Medicine group in Uppsala for their assistance with genotyping.
Figure 3 (facing page). Correlation of Variants in ITGAM-ITGAX with Systemic Lupus Erythematosus.
Panel A shows the −log 10 P values from the ITGAM-ITGAX region. The colors of the diamonds represent the r 2 correlations with rs11574637. All genes in the region (from the Reference Sequence database of the National Center for Biotechnology Information) are displayed above a plot showing the linkage disequilibrium in the region, as determined by analysis of control chromosomes. Blocks connecting pairs of SNPs are shaded according to the strength of the linkage disequilibrium between the SNPs, from 0.0 (white) to 1.0 (bright red), as measured by the disequilibrium coefficient D′. Panel B depicts the genomic structure of ITGAM, the conserved major protein domains, and the relationship between rs11574637 and two nonsynonymous alleles of ITGAM.
